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Psychological disorders are responsible for the largest 
proportion of the global burden of disease worldwide 
(Whiteford et al., 2015). It has been suggested that by 2030, 
depression will be the leading cause of disease burden 
globally (Lépine & Briley, 2011). Uncontrolled 
excitotoxicity and neuroinflammation contribute to cell 
death and damage in neurological and neuropsychiatric 
diseases, including some that are related to stress 
exposure (neurodegenerative diseases, depression, post-
traumatic stress disorder, and schizophrenia) (Tay et al., 
2017). 
Cannabis is touted to effectively attenuate a wide range 
of conditions, including asthma, inflammatory bowel 
disease, glaucoma, multiple sclerosis, menstrual cramps, 
AIDS, nausea, and cancer (Bruni et al., 2018). Delta-9-
tetrahydrocannabinol (THC) is the principal 
psychoactive constituent of cannabis, and most, if not all, 
of the effects associated with the use of cannabis, are 
caused by THC (Kimura et al., 2019). Beyond these effects 
on physical conditions, cannabis has been reported to 
improve neurocognitive and psychiatric conditions, such 
as Alzheimer's disease, anxiety disorders, and bipolar 
disorder (Abizaid et al., 2019; Sarris et al., 2020; Burggren 
et al., 2019). The endocannabinoid system (ECS) plays key 
modulatory roles during synaptic plasticity and 
homeostatic brain processes (Lu & Mackie, 2016). 
This review discusses some relationships between the 
cannabinoid (CB1 and CB2) receptors and their ligands 
with the nervous system in health and disease. We will 
introduce the two major receptors, focusing on the CB1 
receptors due to their high expression levels in the CNS. 
Their endogenous ligands or endocannabinoids (ECB) 
and some synthetic mimetics that activate and modulate 
their signaling; the signaling pathways that connect this 
 
Role of Cannabinoid Receptors in Psychological Disorder 
 
 
Ambika Nand Jha 1*  
Dhaval M. Patel 2  
 
1Department of Pharmacy Practice, 
Indubhai Patel College of Pharmacy and 
Research Center, Dharmaj, Gujarat, 
India 
 
2Department of Pharmacology, SAL 













Cannabinoid receptors, located throughout the body, are part of the 
endocannabinoid system. Cannabinoid CB1 and CB2 receptors are G 
protein-coupled receptors present from the early stages of gestation, 
which is involved in various physiological processes, including 
appetite, pain-sensation, mood, and memory. Due to the lipophilic 
nature of cannabinoids, it was initially thought that these compounds 
exert several biological effects by disrupting the cell membrane 
nonspecifically. Recent biochemical and behavioral findings have 
demonstrated that blockade of CB1 receptors engenders 
antidepressant-like neurochemical changes (increases in extracellular 
levels of monoamines in cortical but not subcortical brain regions) and 
behavioral effects consistent with antidepressant/antistress activity. 
We aim to define various roles of cannabinoid receptors in modulating 
signaling pathways and association with several pathophysiological 
conditions. 
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receptor to processes inside the cell; and the role of the CB 
system in the normally functioning CNS and its 
alteration or therapeutic modulation in a variety of 
disease states (Tanaka et al., 2020). 
 
OVERVIEW OF ENDOCANNABINOID 
SYSTEM 
Before discussing the ECS’s functions, it is essential to 
understand its components. The ECS comprises 
cannabinoid receptors, endogenous ligands (binding 
molecules) for those receptors, and enzymes that 
synthesize and degrade the ligands (Stasiulewicz et al., 
2020). Exogenous cannabinoids, such as 
tetrahydrocannabinol, produce their biological effects 
through their interactions with cannabinoid receptors. 2-
arachidonoyl glycerol (2-AG) and arachidonoyl 
ethanolamide (anandamide) are the best-studied 
endogenous cannabinoids (Lu & Mackie, 2016). 
The most well-known cannabinoid receptors are CB1 
and CB2. Studies in the early 1990s provided initial 
evidence of the existence and purpose of CB1 and CB2 
receptors. Both types of cannabinoid receptors are found 
throughout the entire body but are distributed differently 
(Zou & Kumar, 2018). The CB1 receptors are 
concentrated primarily in the Central Nervous System, 
are most highly expressed by the axons and presynaptic 
terminal of neurons in the amygdala, hippocampus, 
cortex, basal ganglia outflow tracts, and cerebellum 
(Castillo et al., 2012). In contrast, CB2 receptors are mainly 
found in the immune system (Turcotte et al., 2016). 
However, CB1 receptors are also distributed in various 
peripheral areas like adipose (fat) tissue, and CB2 
receptors are expressed to some degree in the brain 
(Howlett & Abood, 2017). 
G protein-coupled receptor (GPCR) domains comprise 
the extracellular N terminus, seven-transmembrane 
alpha-helices (TM), loops connecting the TMs, and an 
intracellular C terminus. Ligand binding generally occurs 
within a binding site gap formed by the TM bundle, 
directly to a pocket formed by the extracellular loops, or 
to a combination of extracellular loop and binding site 
gap residues (Wheatley et al., 2012). Binding induces a 
conformational change in the receptor, causing activation 
of a G protein docked to the inner face, which initiates a 
specific cellular process (Black et al., 2016). 
In general, an agonist-bound receptor activates an 
appropriate G protein that promotes dissociation of 
GDP. The GPCR ligands fall into four categories 
depending on the nature of their interaction: agonists, 
antagonists, partial agonists, and inverse agonists (Weis 
& Kobilka, 2018). Agonists bind to the receptor and elicit 
a cellular response by causing a conformational change. 
Antagonists bind, prevent agonists from binding, and do 
not elicit any response. A partial agonist is an 
intermediate class that, upon binding, does not invoke 
the complete agonist conformational change but still 
allows for partial activity. Simultaneously, they “block” 
the receptor from being available for full agonist binding. 
When both a full agonist and partial agonist are present, 
the partial agonist acts as a competitive antagonist, 
producing a net decrease in the receptor’s activation. 
Inverse agonists bind to a receptor but induce a 
physiological response opposite to what would be 
expected from an agonist (Shahbazi et al., 2020; Berg & 
Clarke, 2018). The affinity of a ligand for the receptor is 
independent of the role: weakly binding full agonists and 
strongly binding partial agonists are both known 
(Buchwald, 2019; Patel et al., 2019). 
Agonists targeting CB2 receptors have been proposed to 
treat or manage a range of painful conditions, including 
acute pain, chronic inflammatory pain, and neuropathic 
pain (Dhopeshwarkar & Mackie, 2014; Vučković et al., 
2018; Donvito et al., 2018). The ECB system is primarily 
composed of two inhibitory GPCRs, CB1 and CB2, and 
Jha AN, Patel DM. 2020. Role of Cannabinoid Receptors in Psychological Disorder 
201 
two major endogenous ligands, N-
arachidonoylethanolamine (anandamide/AEA) and 2-
arachidonoylglycerol (2-AG). Besides, ECB signaling is 
highly regulated by metabolic enzymes, including fatty 
acid amide hydrolase (FAAH) and monoacylglyceride 
lipase (MAGL), hydrolyze AEA and 2-AG, respectively 
(Figure 1) (Meyer et al., 2018). 
 
Figure 1. Major pathways of endocannabinoid degradation 
(Meyer et al., 2018) 
 
CANNABINOID RECEPTORS IN 
ANXIETY 
Anxiety disorders, the most prevalent of the psychiatric 
disorders, cause immeasurable suffering worldwide. 
Despite impressive advances in pharmacological 
therapies, improvements in efficacy and side-effect 
profiles are needed. Anxiety causes chemical changes in 
the limbic system, including the amygdala, 
hippocampus, and hypothalamus of the brain (Zou & 
Kumar, 2018). The present literature review examines the 
role that the endocannabinoid system may play in these 
disorders and the potential value of targeting this system 
to search for novel and improved medications (Patel et al., 
2017; Kayser et al., 2019). 
The neural mechanisms by which endocannabinoid 
signaling affects anxiety are not well understood, yet 
several mechanisms at the systems, synaptic, and 
molecular level can be posed based on available data. The 
majority of available data indicate that ECS has anxiolytic 
properties in both conditioned and unconditioned 
anxiety models and that these effects are more active 
during states of stress or high arousal (Stasiulewicz et al., 
2020; Patel & Hillard, 2009). Endocannabinoid signaling's 
anxiolytic effects are mimicked by low doses of direct 
CB1 receptor agonists (Hill et al., 2018). Thus, data 
exploiting this phenomenon can be used to increase our 
understanding of the neural mechanisms subserving the 
endocannabinoid signaling system's anxiolytic actions 
(Patel & Hillard, 2009). 
At the systems level, microinjections of low doses of the 
direct CB1 agonist THC into the prefrontal cortex (PFC) 
(Rubino et al., 2008), ventral hippocampus, and a dorsal 
periaqueductal gray area exert anxiolytic effects in the 
elevated plus-maze (Moreira et al., 2007). Stress relief and 
relaxation are frequently reported as drivers of cannabis 
use (Turna et al., 2017). These effects are blocked by the 
CB1 receptor antagonist AM251 (Boctor et al., 2007). 
Pharmacological inhibition of FAAH within the PFC 
produces CB1 receptor-dependent, anxiolytic effects, and 
over-expression of FAAH (which reduces local N-
arachidonoylethanolamine levels) causes the anxiogenic 
effect in the elevated plus-maze (Navarrete et al., 2020; 
Lutz et al., 2015). 
In contrast to the PFC and hippocampus, very low THC 
doses produce only anxiogenic effects when 
administered into the basolateral amygdala (BLA); this 
was also dependent upon CB1 receptor activation. These 
data suggest that the PFC and hippocampus are likely 
anatomical sites of action that subserve ECS's anxiolytic 
effects. More specifically, the balance of ECS in favor of an 
increase in the PFC plus hippocampus and reduced 
signaling in the amygdala could be required for maximal 
anxiolytic effects (Patel & Hillard, 2009). 
Endocannabinoid signaling differs from that of classical 
neurotransmitters. They are synthesized on demand in 
post-synaptic neurons in response to neuronal activation 
and act on their targets located presynaptically or in the 
post-synaptic neuron itself to mediate retrograde or non-
retrograde signaling, respectively (Kano, 2014). 
Endocannabinoids act on presynaptic CB1 receptors 
during retrograde signaling to suppress in response to 
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stimuli, which normally provoke anxiety. Both the 
anxiogenic and psychotropic effects of THC would 
appear to preclude its use for treating anxiety-related 
disorders, at least when administered on its own (Lee et 
al., 2017; Papagianni et al., 2019). 
 
NEURAL MECHANISMS OF 
ENDOCANNABINOID MODULATION IN 
DEPRESSION 
The neurobiology of depression is complex; however, a 
large body of evidence supports the hypothesis that 
dysregulation of the Hypothalamic-Pituitary-Adrenal 
axis (HPA axis) plays a critical role (Hasler, 2010). In 
particular, HPA axis hyperactivation and reduced 
feedback inhibition are seen in humans with depression 
and in animal models of depression. Anti-depressants' 
ability to suppress HPA axis hyperactivity is coupled 
with their clinical efficacy (Herman et al., 2016). 
Recent studies strongly suggest that the ECS's primary 
role is to dampen HPA axis activation by stress and allow 
for appropriate stress recovery (Stephens & Wand, 2012). 
These findings are consistent with the data obtained in 
rodents described above that ECS inhibition is generally 
pro-depressive. Simultaneously, its activation results in 
an anti-depressant phenotype and leads to the 
hypothesis that the HPA axis's dampening is the 
mechanism by which ECS interacts with depression. 
However, HPA axis inhibition does not entirely explain 
ECS's effects to alter coping behaviors in the forced swim 
assay (Barden, 2004). Poleszak et al. (2020) evaluated the 
potential interaction between the CB2 receptor ligands 
(i.e., JWH133 – CB2 receptor agonist and AM630 – CB2 
receptor inverse agonist) and several common anti-
depressant drugs that influence the monoaminergic 
system (i.e., imipramine, escitalopram, reboxetine) 
(Ibarra-Lecue et al., 2018). Cannabis amotivational 
syndrome is based on apparent apathy and abolished the 
ability to concentrate and follow routine life observed in 
those who consume marijuana frequently (Volkow et al., 
2016). There is both preclinical and clinical evidence 
supporting the view that cannabis use is associated with 
an amotivational state (Lawn et al., 2016). Considerable 
research has failed to identify a cannabis-specific 
motivational syndrome, and its existence remains 
controversial. A study by Lac and Luk (2018) sought to 
elucidate amotivational syndrome by examining 
connections between marijuana use and self-efficacy 
constructs of initiative, effort, and persistence. Results 
showed that marijuana intake was significantly 
longitudinally related to lower initiative and persistence 
in their college student sample. Due to this, higher dose 
THC should be avoided in people with major depressive 
disorder (MDD) or low mood. However, a cross-
sectional survey on patterns of use and perceived efficacy 
suggested that over 1429 participants identified as 
medical cannabis users, over 50% reported using 
medicinal cannabis specifically for depression (Sarris et 
al., 2020). Various medicinal cannabis trials in mental 
disorders are listed in Table I, while various EC system 
changes in neurodegenerative disorders are listed in 
Table II. 
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Table II. Changes in EC system in neurodegenerative 
disorders 
Study model Changes in EC system 
Changes in the EC system 
components in Alzheimer 
diseases, Preclinical 
studies, AbPPswe/PS1DE9 
model of AD (Maroof et al., 
2014) 
< Striatal AG level 
> CBR/effector coupling 
Changes in the EC system 
components in Parkinson’s 
diseases, Pre-clinical 
studies, Reserpine treated 
rats (Di Marzo et al., 2000) 
> 2-AG in globus pallidus 
Impaired locomotion 
> AEA in globus pallidus & 
substantia nigra 




clinical studies, Ab injected 
rats (Ramirez et al., 2005) 
< Ab induced microglial 
activation 
< Cognitive impairment 
 
CANNABINOID RECEPTOR IN EPILEPSY 
Cannabidiol good affinity at the plausible concentration 
for 5-HT1A and 5-HT2A receptors, and 5-HT2A 
receptors act as a target for fenfluramine, a drug for 
which some evidence supports efficacy drug-resistant 
epilepsies such as Dravet syndrome (Ceulemans et al., 
2012). A minimal number of studies have reported 
changes in 5-hydroxytryptamine (5-HT) receptor 
expression and function in people with epilepsy, 
although it remains unclear whether this is a 
consequence of the disease or a component of 
pathogenesis. Thus, while 5-HT involvement in 
pathogenesis remains uncertain, some 5-HT receptor 
subtypes may represent a valid therapeutic target in 
epilepsy through which CBD could be acting (Theodore 
et al., 2007; Theodore et al., 2012). Glycine receptor (GlyR) 
is predominantly expressed in the CNS, neuronal cells, 
brainstem, and spinal cord, and there is much less 
evidence of their role in disorders of the cerebrum, such 
as epilepsy. However, recent research in rodent species 
has shown significant, functional GlyR expression in 
cortex and hippocampus at least up to postnatal day 14, 
where they serve to modulate neuronal network function 
(Avila et al., 2013), and emerging evidence suggests a role 
in hyperexcitability disorders (Harvey et al., 2008). These 
findings suggest that investigation of GlyR function in 
healthy and epileptic, mature human cortex is warranted 
in order to lend further credence to GlyR-mediated 
antiepileptic effects of CBD. 
 
CANNABINOID RECEPTORS IN 
ALZHEIMER’S DISEASE 
Alzheimer's disease (AD) is the most common 
neurodegenerative disease in Western Europe, and a 
significant public health problem as the number of cases 
increases with the aging of the population. It manifests 
with a progressive decline in memory and intellectual 
abilities, impoverishment of language, disorientation, 
and behavioral skills (Mayeux & Stern, 2012). The AD is 
also characterized by enhanced beta-amyloid peptide 
(Aβ) deposition and glial activation in senile plaques, 
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selective neuronal loss, and cognitive deficits (Licastro & 
Chiappelli, 2003). The role of cannabinoid receptors in 
AD and their possible protective effects after Aβ 
treatment showed that senile plaques in AD patients 
express CB1 and CB2 cannabinoid receptors and 
markers of microglial activation (Pizza et al., 2011). 
Furthermore, while high levels of CB1-positive neurons 
are present in control cases, they are significantly reduced 
in microglial activation areas. Also, G-protein coupling 
and CB1 receptor protein expression are markedly 
decreased in AD brains where protein nitration is 
increased (Ramirez et al., 2005). Cannabinoids prevent 
both Aβ-induced microglial activation, cognitive 
impairment, and loss of neuronal markers and abrogate 
microglia-mediated neurotoxicity after Aβ addition to rat 
cortical cocultures. These results indicate that 
cannabinoid receptors are involved in the pathology of 
AD and that they may control the neurodegenerative 
process occurring in the disease (Cassano et al., 2017). 
 
CONCLUSION 
Stress-related mood and anxiety disorders affect millions 
of people in the United States. Endocannabinoids are 
lipids that act as a kind of a neurotransmitter. Mainly, 
they activate the CB1 and CB2 brain receptors. CB1 can 
be found in several brain areas, including the neocortex, 
the hippocampus, the amygdala, the cerebellum, and the 
hypothalamus. These brain areas are involved in 
emotional and behavioral reactions, homeostasis, 
learning, memory, and decision-making. The effects on 
emotion mediated by cannabinoid compounds are 
believed to be due to regulating activity at the 
cannabinoid CB1 receptors. However, some limited 
evidence implicates the cannabinoid CB2 and a putative 
novel cannabinoid receptor (GPR55) in some observed 
emotional responses. Effects on emotion are likely the 
result of a net effect of the summated neurochemical 
responses. Compounds that indirectly regulate activity at 
the cannabinoid receptors more consistently reduce 
anxiety both in preclinical and clinical models. 
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